Tango-Tiger

Israeli biotech company completes clinical trial of new drug for the treatment of Covid-19.
The drug, called slotxo MesenCure, was developed by Bonus Biogroup for the treatment of life-threatening dyspnea among Covid-19 patients.

Mesenkyo contains adipose stem cells (ADSC) from healthy donors. The patient will receive the drug through a blood transfusion. The company said the drug can reduce inflammation in the lung tissue. Including helping with the recovery process


about a year ago Successful animal trials of Mesencio The government therefore approved a human clinical trial at the Rumbaum Medical Center. northern israel Some of the participants were COVID-19 patients. Severe symptoms, aged between 45-75 years, 10 cases

Those patients had acute respiratory distress symptoms. Serious pneumonia and have a dangerous immune response. In addition, most of these patients also had other complications.

After receiving the drug, the patients improved and were released from the hospital an average of one day after treatment ended.

Mesenkyo can help patients move better and perform daily activities. It also helps alleviate pain and anxiety.

In the next phase, the company will conduct trials on 50 additional patients, and Mesencure will be administered to a group of patients at Rambam hospital.